{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:24:02Z","timestamp":1788279842268,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T00:00:00Z","timestamp":1341446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/hr.2012.96","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T11:42:17Z","timestamp":1341488537000},"page":"1058-1062","source":"Crossref","is-referenced-by-count":21,"title":["Renoprotective and antioxidant effects of cilnidipine in hypertensive patients"],"prefix":"10.1038","volume":"35","author":[{"given":"Takeshi","family":"Soeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Kusunose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Taketani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Koshiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Orino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,5]]},"reference":[{"key":"BFhr201296_CR1","doi-asserted-by":"publisher","first-page":"c47","DOI":"10.1159\/000086221","volume":"101","author":"K Kundhal","year":"2005","unstructured":"Kundhal K, Lok CE . Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 2005; 101: c47\u2013c52.","journal-title":"Nephron Clin Pract"},{"key":"BFhr201296_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861\u2013869.","journal-title":"N Engl J Med"},{"key":"BFhr201296_CR3","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright","year":"2002","unstructured":"Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421\u20132431.","journal-title":"JAMA"},{"key":"BFhr201296_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1291\/hypres.24.377","volume":"24","author":"GW Rose","year":"2001","unstructured":"Rose GW, Kanno Y, Ikebukuro H, Kaneko M, Kaneko K, Kanno T, Ishida Y, Suzuki H . Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24: 377\u2013383.","journal-title":"Hypertens Res"},{"key":"BFhr201296_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1291\/hypres.27.379","volume":"27","author":"S Kojima","year":"2004","unstructured":"Kojima S, Shida M, Yokoyama H . Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379\u2013385.","journal-title":"Hypertens Res"},{"key":"BFhr201296_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851\u2013860.","journal-title":"N Engl J Med"},{"key":"BFhr201296_CR7","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.ki.5002623","volume":"72","author":"T Fujita","year":"2007","unstructured":"Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K . Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease (CARTER) Study investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543\u20131549.","journal-title":"Kidney Int"},{"key":"BFhr201296_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000085713","volume":"101","author":"T Konda","year":"2005","unstructured":"Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T . The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101: 1\u201313.","journal-title":"Nephron Physiol"},{"key":"BFhr201296_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/ki.2009.146","volume":"76","author":"K Hishikawa","year":"2009","unstructured":"Hishikawa K, Takase O, Idei M, Fujita T . Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76: 230\u2013231.","journal-title":"Kidney Int"},{"key":"BFhr201296_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/10590500902885684","volume":"27","author":"A Valavanidis","year":"2009","unstructured":"Valavanidis A, Vlachogianni T, Fiotakis C . 8-Hydroxy-2'-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009; 27: 120\u2013139.","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"BFhr201296_CR11","first-page":"39","volume":"107","author":"S Saito","year":"2000","unstructured":"Saito S, Yamauchi H, Hasui Y, Kurashige J, Ochi H, Yoshida K . Quantitative determination of urinary 8-hydroxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol 2000; 107: 39\u201344.","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"BFhr201296_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.phrs.2009.04.011","volume":"60","author":"T Nakamura","year":"2009","unstructured":"Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Adachi H, Okuda S, Yamagishi S . Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525\u2013528.","journal-title":"Pharmacol Res"},{"key":"BFhr201296_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.lab.2004.12.003","volume":"145","author":"A Kamijo","year":"2005","unstructured":"Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K . Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145: 125\u2013133.","journal-title":"J Lab Clin Med"},{"key":"BFhr201296_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2353\/ajpath.2009.080511","volume":"174","author":"T Tanaka","year":"2009","unstructured":"Tanaka T, Doi K, Maeda-Mamiya R, Negishi K, Portilla D, Sugaya T, Fujita T, Noiri E . Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 2009; 174: 1203\u20131211.","journal-title":"Am J Pathol"},{"key":"BFhr201296_CR15","first-page":"3","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H . The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3\u2013107.","journal-title":"Hypertens Res"},{"key":"BFhr201296_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5551\/jat.E537","volume":"14","author":"T Teramoto","year":"2007","unstructured":"Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M . Japan Atherosclerosis Society (JAS) Committee for epidemiology and clinical management of atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 155\u2013158.","journal-title":"J Atheroscler Thromb"},{"key":"BFhr201296_CR17","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ . The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560\u20132572.","journal-title":"JAMA"},{"key":"BFhr201296_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O\u2019Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105\u20131187.","journal-title":"J Hypertens"},{"key":"BFhr201296_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1472-8206.2004.00236.x","volume":"18","author":"A Nap","year":"2004","unstructured":"Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA . The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists. Fundam Clin Pharmacol 2004; 18: 309\u2013319.","journal-title":"Fundam Clin Pharmacol"},{"key":"BFhr201296_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","volume":"100","author":"K Hayashi","year":"2007","unstructured":"Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T . Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342\u2013353.","journal-title":"Circ Res"},{"key":"BFhr201296_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/00004872-200205000-00035","volume":"20","author":"X Zhou","year":"2002","unstructured":"Zhou X, Ono H, Ono Y, Frohlichzzz ED . N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME\/SHR model. J Hypertens 2002; 20: 993\u20131000.","journal-title":"J Hypertens"},{"key":"BFhr201296_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/hh1901.097126","volume":"89","author":"PB Hansen","year":"2001","unstructured":"Hansen PB, Jensen BL, Andreasen D, Sk\u00f8tt O . Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630\u2013638.","journal-title":"Circ Res"},{"key":"BFhr201296_CR23","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1089\/ars.2008.2034","volume":"10","author":"R Nistala","year":"2008","unstructured":"Nistala R, Whaley-Connell A, Sowers JR . Redox control of renal function and hypertension. Antioxid Redox Signal 2008; 10: 2047\u20132089.","journal-title":"Antioxid Redox Signal"},{"key":"BFhr201296_CR24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1161\/01.RES.66.5.1449","volume":"66","author":"IT Mak","year":"1990","unstructured":"Mak IT, Weglicki WB . Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990; 66: 1449\u20131452.","journal-title":"Circ Res"},{"key":"BFhr201296_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1248\/yakushi.128.117","volume":"128","author":"Y Uesawa","year":"2008","unstructured":"Uesawa Y, Mohri K . Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice. Yakugaku Zasshi 2008; 128: 117\u2013122.","journal-title":"Yakugaku Zasshi"},{"key":"BFhr201296_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/HJH.0b013e328336ade3","volume":"28","author":"YY Fan","year":"2010","unstructured":"Fan YY, Kohno M, Nakano D, Ohsaki H, Kobori H, Suwarni D, Ohashi N, Hitomi H, Asanuma K, Noma T, Tomino Y, Fujita T, Nishiyama A . Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J Hypertens 2010; 28: 1034\u20131043.","journal-title":"J Hypertens"},{"key":"BFhr201296_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/hr.2010.279","volume":"34","author":"H Toba","year":"2011","unstructured":"Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T . L\/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertens Res 2011; 34: 521\u2013529.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr201296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201296","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:11:59Z","timestamp":1684429919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,5]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFhr201296"],"URL":"https:\/\/doi.org\/10.1038\/hr.2012.96","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,5]]}}}